Schering-Plough makes changes in its R&D operations

Schering-Plough has made several changes in its research and development operations. Thomas Koestler, Ph.D., was promoted to executive vice president, global development, Schering-Plough Research Institute (SPRI) and James MacDonald, Ph.D., was promoted to executive vice president, preclinical development, SPRI; both report to Cecil Pickett, Ph.D., senior vice president and president, SPRI. Koestler and MacDonald will both continue as members of the Operations Management Team (OMT), also.
Koestler will set strategic direction and implementation plans for the new development organization, which will include worldwide clinical development, pharmaceutical sciences, global regulatory affairs and global project management. Before joining Schering-Plough in 2003 as executive vice president, global regulatory affairs and global project management, Koestler was senior vice president, global regulatory affairs, Pharmacia Corporation.
MacDonald will continue to have direct responsibility for the drug safety and metabolism group as well as the newly created SPRI computer validation group. He will be responsible for assuring a steady flow of new compounds for the development pipeline by establishing effective working relationships with the appropriate groups in discovery, pharmaceutical sciences and clinical research. MacDonald joined Schering-Plough in 1994 as senior vice president, drug, safety and metabolism.
"These changes are designed to further strengthen Schering-Plough Research Institute's development operations worldwide, as we transform the company into a successful global competitor beginning with our anticipated turnaround this year," said Fred Hassan, chairman and chief executive, Schering-Plough.

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.